Accordingly, it was shown that acute exenatide injection in a mouse model of the disease enhances insulin secretion (Sedman et al., 2016) and that prolonged exenatide and liraglutide administration in WFS1-deficient mice and rats prevent glucose intolerance and improve glucose-stimulated insulin secretion by reducing cellular stress (Kondo et al., 2018; Toots et al., 2018). This evidence concerns the gene INS and Glucose intolerance.